Updated on 2023/12/25

写真a

 
TANAKA Rinako
 
Organization
Nagoya University Hospital Department of Hospital Pharmacy Designated assistant professor
Title
Designated assistant professor
External link

Degree 1

  1. Doctor (Medicine) ( 2023.3   Nagoya University ) 

Research Areas 1

  1. Life Science / Psychiatry

Research History 1

  1. Nagoya University   Nagoya University Hospital Department of Hospital Pharmacy   Designated assistant professor

    2023.4

Education 2

  1. Nagoya University   Graduate School of Medicine

    2019.4 - 2023.3

      More details

    Country: Japan

  2. Nagasaki University

    2013.4 - 2019.3

      More details

    Country: Japan

Professional Memberships 2

  1. 日本神経精神薬理学会

    2021.7

  2. 日本薬理学会

    2020.10

Awards 3

  1. JSNP Excellent Presentation Award for AsCNP 2021

    2021.10   The Japanese Society of Neuropsychopharmacology   Effect of a Rho-kinase inhibitor, fasudil, on spine density in the mPFC of mice carrying a mutation of the Arhgap10 gene

    Rinaka Tanaka

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:Singapore

  2. Nabeshima Award

    2021.10   The Japanese Society of Neuropsychopharmacology   Effect of a Rho-kinase inhibitor, fasudil, on spine density in the mPFC of mice carrying a mutation of the Arhgap10 gene

    Rinaka Tanaka

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:Singapore

  3. ePoster Best Presentation Award

    2021.6   The 23rd Korea-Japan Joint Seminar on Pharmacology   Effect of fasudil in a pharmacologic animal model of schizophrenia

    Rinako Tanaka

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:Korea, Republic of

 

Papers 3

  1. Genomic and Reverse Translational Analysis Discloses a Role for Small GTPase RhoA Signaling in the Pathogenesis of Schizophrenia: Rho-Kinase as a Novel Drug Target

    Tanaka, R; Yamada, K

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   Vol. 24 ( 21 )   2023.11

     More details

    Language:English   Publisher:International Journal of Molecular Sciences  

    Schizophrenia is one of the most serious psychiatric disorders and is characterized by reductions in both brain volume and spine density in the frontal cortex. RhoA belongs to the RAS homolog (Rho) family and plays critical roles in neuronal development and structural plasticity via Rho-kinase. RhoA activity is regulated by GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). Several variants in GAPs and GEFs associated with RhoA have been reported to be significantly associated with schizophrenia. Moreover, several mouse models carrying schizophrenia-associated gene variants involved in RhoA/Rho-kinase signaling have been developed. In this review, we summarize clinical evidence showing that variants in genes regulating RhoA activity are associated with schizophrenia. In the last half of the review, we discuss preclinical evidence indicating that RhoA/Rho-kinase is a potential therapeutic target of schizophrenia. In particular, Rho-kinase inhibitors exhibit anti-psychotic-like effects not only in Arhgap10 S490P/NHEJ mice, but also in pharmacologic models of schizophrenia (methamphetamine- and MK-801-treated mice). Accordingly, we propose that Rho-kinase inhibitors may have antipsychotic effects and reduce cognitive deficits in schizophrenia despite the presence or absence of genetic variants in small GTPase signaling pathways.

    DOI: 10.3390/ijms242115623

    Web of Science

    Scopus

    PubMed

  2. Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene Reviewed

    Tanaka Rinako, Liao Jingzhu, Hada Kazuhiro, Mori Daisuke, Nagai Taku, Matsuzaki Tetsuo, Nabeshima Toshitaka, Kaibuchi Kozo, Ozaki Norio, Mizoguchi Hiroyuki, Yamada Kiyofumi

    PHARMACOLOGICAL RESEARCH   Vol. 187   page: 106589   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Pharmacological Research  

    Copy-number variations in the ARHGAP10 gene encoding Rho GTPase–activating protein 10 are associated with schizophrenia. Model mice (Arhgap10 S490P/NHEJ mice) that carry “double-hit” mutations in the Arhgap10 gene mimic the schizophrenia in a Japanese patient, exhibiting altered spine density, methamphetamine-induced cognitive dysfunction, and activation of RhoA/Rho-kinase signaling. However, it remains unclear whether the activation of RhoA/Rho-kinase signaling due to schizophrenia-associated Arhgap10 mutations causes the phenotypes of these model mice. Here, we investigated the effects of fasudil, a brain permeable Rho-kinase inhibitor, on altered spine density in the medial prefrontal cortex (mPFC) and on methamphetamine-induced cognitive impairment in a touchscreen‑based visual discrimination task in Arhgap10 S490P/NHEJ mice. Fasudil (20 mg/kg, intraperitoneal) suppressed the increased phosphorylation of myosin phosphatase–targeting subunit 1, a substrate of Rho-kinase, in the striatum and mPFC of Arhgap10 S490P/NHEJ mice. In addition, daily oral administration of fasudil (20 mg/kg/day) for 7 days ameliorated the reduced spine density of layer 2/3 pyramidal neurons in the mPFC. Moreover, fasudil (3–20 mg/kg, intraperitoneal) rescued the methamphetamine (0.3 mg/kg)-induced cognitive impairment of visual discrimination in Arhgap10 S490P/NHEJ mice. Our results suggest that Rho-kinase plays significant roles in the neuropathological changes in spine morphology and in the vulnerability of cognition to methamphetamine in mice with schizophrenia-associated Arhgap10 mutations.

    DOI: 10.1016/j.phrs.2022.106589

    Web of Science

    Scopus

    PubMed

  3. Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia Reviewed

    Saeko Takase, Jingzhu Liao, Yue Liu, Rinako Tanaka, Yasuhiro Miyagawa, Masahito Sawahata, Akira Sobue, Hiroyuki Mizoguchi, Taku Nagai, Kozo Kaibuchi, Norio Ozaki, Kiyofumi Yamada

    European Journal of Pharmacology   Vol. 931   page: 175207   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ejphar.2022.175207

Presentations 8

  1. Fasudil ameliorates methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated gene mutations in the Arhgap10 gene International conference

    2023.7.4 

     More details

    Event date: 2023.7

    Language:English  

    Country:United Kingdom  

  2. Effect of a Rho-kinase inhibitor, fasudil, on spine density in the mPFC of mice carrying a mutation of the Arhgap10 gene International conference

    Rinako Tanaka

    7th Congress of AsCNP 2021  2021.10.22 

     More details

    Event date: 2021.10

    Language:English   Presentation type:Poster presentation  

    Country:Singapore  

  3. マウスとラットの種差による肝臓表面投与時の薬物動態の差異に関する研究

    田中里奈子

    第34回日本薬学会九州支部大会  2017.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  4. Establishment of an in vivo calcium imaging method to evaluate neuronal activity in mice carrying mutations of Arhgap10 gene

    Rinako Tanaka

    2022.3.8 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:Japan  

  5. Effects of a Rho-kinase inhibitor, fasudil on schizophrenia-like behavior and neurotransmitter release in MK-801-treated mice

    2021.3.8 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  6. Effect of fasudil in a pharmacologic animal model of schizophrenia International conference

    Rinako Tanaka

    The 23rd Korea-Japan Joint Seminar on Pharmacology  2021.6.25 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:Korea, Republic of  

  7. マウスにおけるMK-801誘発性行動異常におけるRhoキナーゼの役割

    田中里奈子

    第43回日本生物学的精神医学会・第51回日本神経精神薬理学会合同年会  2021.7.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:京都   Country:Japan  

  8. Fasudil ameliorates methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated gene mutations in the Arhgap10 gene International conference

    Rinako Tanaka

    19th World Congress of Basic & Clinical Pharmacology 2023  2023.7.4 

     More details

    Language:English  

    Country:United Kingdom  

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 統合失調症患者のゲノム解析を基盤とした新規治療戦略の創生

    Grant number:23K19425  2023.8 - 2025.3

    科学研究費助成事業  研究活動スタート支援

    田中 里奈子

      More details

    Authorship:Principal investigator 

    Grant amount:\2860000 ( Direct Cost: \2200000 、 Indirect Cost:\660000 )